REPORT ID 2114

Asia-Pacific Non-Insulin Therapies for Diabetes Market Report 2017

Publish Date
7-Dec-17
Pages
114
Format
Electronic (PDF)

In this report, the Asia-Pacific Non-Insulin Therapies for Diabetes market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (), revenue (Million USD), market share and growth rate of Non-Insulin Therapies for Diabetes for these regions, from 2012 to 2022 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

Asia-Pacific Non-Insulin Therapies for Diabetes market competition by top manufacturers/players, with Non-Insulin Therapies for Diabetes sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    GSK
    Eli Lilly
    Sumitomo Dainippon Pharma
    Intarcia Therapeutics
    Servier
    Jiangsu Hansoh Pharmaceutical
    Novo Nordisk
    Emisphere
    Uni-Bio Science Group
    Takeda
    3SBio
    Merck
    Dong-A Pharmaceutical
    Luye Pharma Group
    Eurofarma
    Geropharm
    Alkem Labs
    SatRx
    Pfizer
    Jiangsu Hengrui Medicine

On the basis of product, this report displays the sales volume (), revenue (Million USD), product price (), market share and growth rate of each type, primarily split into
    Alpha-glucosidase Inhibitors
    Amylin Agonists
    Biguanides
    Dipeptidyl Peptidase-4 (DPP4) Inhibitors
    Glinides / Meglitinides
    GLP-1 Analogs / GLP-1 Agonists
    Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
    Sulfonylureas
    Thiazolidinediones
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (), market share and growth rate of Non-Insulin Therapies for Diabetes for each application, includin
    Hospital Pharmacy
    Retail Pharmacies
    Online Pharmacy
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Asia-Pacific Non-Insulin Therapies for Diabetes Market Report 2017
1 Non-Insulin Therapies for Diabetes Overview
    1.1 Product Overview and Scope of Non-Insulin Therapies for Diabetes
    1.2 Classification of Non-Insulin Therapies for Diabetes by Product Category
        1.2.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (Sales) Comparison by Types (2012-2022)
        1.2.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Alpha-glucosidase Inhibitors
        1.2.4 Amylin Agonists
        1.2.5 Biguanides
        1.2.6 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
        1.2.7 Glinides / Meglitinides
        1.2.8 GLP-1 Analogs / GLP-1 Agonists
        1.2.9 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
        1.2.10 Sulfonylureas
        1.2.11 Thiazolidinediones
        1.2.12 Others
    1.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market by Application/End Users
        1.3.1 Asia-Pacific Non-Insulin Therapies for Diabetes Sales (Volume) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Hospital Pharmacy
        1.3.3 Retail Pharmacies
        1.3.4 Online Pharmacy
        1.3.5 Others
    1.4 Asia-Pacific Non-Insulin Therapies for Diabetes Market by Region
        1.4.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 China Status and Prospect (2012-2022)
        1.4.3 Japan Status and Prospect (2012-2022)
        1.4.4 South Korea Status and Prospect (2012-2022)
        1.4.5 Taiwan Status and Prospect (2012-2022)
        1.4.6 India Status and Prospect (2012-2022)
        1.4.7 Southeast Asia Status and Prospect (2012-2022)
        1.4.8 Australia Status and Prospect (2012-2022)
    1.5 Asia-Pacific Market Size (Value and Volume) of Non-Insulin Therapies for Diabetes (2012-2022)
        1.5.1 Asia-Pacific Non-Insulin Therapies for Diabetes Sales and Growth Rate (2012-2022)
        1.5.2 Asia-Pacific Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2022)

2 Asia-Pacific Non-Insulin Therapies for Diabetes Competition by Players/Suppliers, Region, Type and Application
    2.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Competition by Players/Suppliers
        2.1.1 Asia-Pacific Non-Insulin Therapies for Diabetes Sales Volume and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Asia-Pacific Non-Insulin Therapies for Diabetes Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Asia-Pacific Non-Insulin Therapies for Diabetes (Volume and Value) by Type
        2.2.1 Asia-Pacific Non-Insulin Therapies for Diabetes Sales and Market Share by Type (2012-2017)
        2.2.2 Asia-Pacific Non-Insulin Therapies for Diabetes Revenue and Market Share by Type (2012-2017)
    2.3 Asia-Pacific Non-Insulin Therapies for Diabetes (Volume) by Application
    2.4 Asia-Pacific Non-Insulin Therapies for Diabetes (Volume and Value) by Region
        2.4.1 Asia-Pacific Non-Insulin Therapies for Diabetes Sales and Market Share by Region (2012-2017)
        2.4.2 Asia-Pacific Non-Insulin Therapies for Diabetes Revenue and Market Share by Region (2012-2017)

3 China Non-Insulin Therapies for Diabetes (Volume, Value and Sales Price)
    3.1 China Non-Insulin Therapies for Diabetes Sales and Value (2012-2017)
        3.1.1 China Non-Insulin Therapies for Diabetes Sales Volume and Growth Rate (2012-2017)
        3.1.2 China Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2017)
        3.1.3 China Non-Insulin Therapies for Diabetes Sales Price Trend (2012-2017)
    3.2 China Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Type
    3.3 China Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Application

4 Japan Non-Insulin Therapies for Diabetes (Volume, Value and Sales Price)
    4.1 Japan Non-Insulin Therapies for Diabetes Sales and Value (2012-2017)
        4.1.1 Japan Non-Insulin Therapies for Diabetes Sales Volume and Growth Rate (2012-2017)
        4.1.2 Japan Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2017)
        4.1.3 Japan Non-Insulin Therapies for Diabetes Sales Price Trend (2012-2017)
    4.2 Japan Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Type
    4.3 Japan Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Application

5 South Korea Non-Insulin Therapies for Diabetes (Volume, Value and Sales Price)
    5.1 South Korea Non-Insulin Therapies for Diabetes Sales and Value (2012-2017)
        5.1.1 South Korea Non-Insulin Therapies for Diabetes Sales Volume and Growth Rate (2012-2017)
        5.1.2 South Korea Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2017)
        5.1.3 South Korea Non-Insulin Therapies for Diabetes Sales Price Trend (2012-2017)
    5.2 South Korea Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Type
    5.3 South Korea Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Application

6 Taiwan Non-Insulin Therapies for Diabetes (Volume, Value and Sales Price)
    6.1 Taiwan Non-Insulin Therapies for Diabetes Sales and Value (2012-2017)
        6.1.1 Taiwan Non-Insulin Therapies for Diabetes Sales Volume and Growth Rate (2012-2017)
        6.1.2 Taiwan Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2017)
        6.1.3 Taiwan Non-Insulin Therapies for Diabetes Sales Price Trend (2012-2017)
    6.2 Taiwan Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Type
    6.3 Taiwan Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Application

7 India Non-Insulin Therapies for Diabetes (Volume, Value and Sales Price)
    7.1 India Non-Insulin Therapies for Diabetes Sales and Value (2012-2017)
        7.1.1 India Non-Insulin Therapies for Diabetes Sales Volume and Growth Rate (2012-2017)
        7.1.2 India Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2017)
        7.1.3 India Non-Insulin Therapies for Diabetes Sales Price Trend (2012-2017)
    7.2 India Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Type
    7.3 India Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Application

8 Southeast Asia Non-Insulin Therapies for Diabetes (Volume, Value and Sales Price)
    8.1 Southeast Asia Non-Insulin Therapies for Diabetes Sales and Value (2012-2017)
        8.1.1 Southeast Asia Non-Insulin Therapies for Diabetes Sales Volume and Growth Rate (2012-2017)
        8.1.2 Southeast Asia Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2017)
        8.1.3 Southeast Asia Non-Insulin Therapies for Diabetes Sales Price Trend (2012-2017)
    8.2 Southeast Asia Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Type
    8.3 Southeast Asia Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Application

9 Australia Non-Insulin Therapies for Diabetes (Volume, Value and Sales Price)
    9.1 Australia Non-Insulin Therapies for Diabetes Sales and Value (2012-2017)
        9.1.1 Australia Non-Insulin Therapies for Diabetes Sales Volume and Growth Rate (2012-2017)
        9.1.2 Australia Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2017)
        9.1.3 Australia Non-Insulin Therapies for Diabetes Sales Price Trend (2012-2017)
    9.2 Australia Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Type
    9.3 Australia Non-Insulin Therapies for Diabetes Sales Volume and Market Share by Application

10 Asia-Pacific Non-Insulin Therapies for Diabetes Players/Suppliers Profiles and Sales Data
    10.1 GSK
        10.1.1 Company Basic Information, Manufacturing Base and Competitors
        10.1.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.1.2.1 Product A
            10.1.2.2 Product B
        10.1.3 GSK Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.1.4 Main Business/Business Overview
    10.2 Eli Lilly
        10.2.1 Company Basic Information, Manufacturing Base and Competitors
        10.2.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.2.2.1 Product A
            10.2.2.2 Product B
        10.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.2.4 Main Business/Business Overview
    10.3 Sumitomo Dainippon Pharma
        10.3.1 Company Basic Information, Manufacturing Base and Competitors
        10.3.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.3.2.1 Product A
            10.3.2.2 Product B
        10.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.3.4 Main Business/Business Overview
    10.4 Intarcia Therapeutics
        10.4.1 Company Basic Information, Manufacturing Base and Competitors
        10.4.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.4.2.1 Product A
            10.4.2.2 Product B
        10.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.4.4 Main Business/Business Overview
    10.5 Servier
        10.5.1 Company Basic Information, Manufacturing Base and Competitors
        10.5.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.5.2.1 Product A
            10.5.2.2 Product B
        10.5.3 Servier Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.5.4 Main Business/Business Overview
    10.6 Jiangsu Hansoh Pharmaceutical
        10.6.1 Company Basic Information, Manufacturing Base and Competitors
        10.6.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.6.2.1 Product A
            10.6.2.2 Product B
        10.6.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.6.4 Main Business/Business Overview
    10.7 Novo Nordisk
        10.7.1 Company Basic Information, Manufacturing Base and Competitors
        10.7.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.7.2.1 Product A
            10.7.2.2 Product B
        10.7.3 Novo Nordisk Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.7.4 Main Business/Business Overview
    10.8 Emisphere
        10.8.1 Company Basic Information, Manufacturing Base and Competitors
        10.8.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.8.2.1 Product A
            10.8.2.2 Product B
        10.8.3 Emisphere Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.8.4 Main Business/Business Overview
    10.9 Uni-Bio Science Group
        10.9.1 Company Basic Information, Manufacturing Base and Competitors
        10.9.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.9.2.1 Product A
            10.9.2.2 Product B
        10.9.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.9.4 Main Business/Business Overview
    10.10 Takeda
        10.10.1 Company Basic Information, Manufacturing Base and Competitors
        10.10.2 Non-Insulin Therapies for Diabetes Product Category, Application and Specification
            10.10.2.1 Product A
            10.10.2.2 Product B
        10.10.3 Takeda Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
        10.10.4 Main Business/Business Overview
    10.11 3SBio
    10.12 Merck
    10.13 Dong-A Pharmaceutical
    10.14 Luye Pharma Group
    10.15 Eurofarma
    10.16 Geropharm
    10.17 Alkem Labs
    10.18 SatRx
    10.19 Pfizer
    10.20 Jiangsu Hengrui Medicine

11 Non-Insulin Therapies for Diabetes Manufacturing Cost Analysis
    11.1 Non-Insulin Therapies for Diabetes Key Raw Materials Analysis
        11.1.1 Key Raw Materials
        11.1.2 Price Trend of Key Raw Materials
        11.1.3 Key Suppliers of Raw Materials
        11.1.4 Market Concentration Rate of Raw Materials
    11.2 Proportion of Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Manufacturing Process Analysis of Non-Insulin Therapies for Diabetes

12 Industrial Chain, Sourcing Strategy and Downstream Buyers
    12.1 Non-Insulin Therapies for Diabetes Industrial Chain Analysis
    12.2 Upstream Raw Materials Sourcing
    12.3 Raw Materials Sources of Non-Insulin Therapies for Diabetes Major Manufacturers in 2016
    12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders
    13.1 Marketing Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
        13.1.3 Marketing Channel Development Trend
    13.2 Market Positioning
        13.2.1 Pricing Strategy
        13.2.2 Brand Strategy
        13.2.3 Target Client
    13.3 Distributors/Traders List

14 Market Effect Factors Analysis
    14.1 Technology Progress/Risk
        14.1.1 Substitutes Threat
        14.1.2 Technology Progress in Related Industry
    14.2 Consumer Needs/Customer Preference Change
    14.3 Economic/Political Environmental Change

15 Asia-Pacific Non-Insulin Therapies for Diabetes Market Forecast (2017-2022)
    15.1 Asia-Pacific Non-Insulin Therapies for Diabetes Sales Volume, Revenue and Price Forecast (2017-2022)
        15.1.1 Asia-Pacific Non-Insulin Therapies for Diabetes Sales Volume and Growth Rate Forecast (2017-2022)
        15.1.2 Asia-Pacific Non-Insulin Therapies for Diabetes Revenue and Growth Rate Forecast (2017-2022)
        15.1.3 Asia-Pacific Non-Insulin Therapies for Diabetes Price and Trend Forecast (2017-2022)
    15.2 Asia-Pacific Non-Insulin Therapies for Diabetes Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.1 Asia-Pacific Non-Insulin Therapies for Diabetes Sales Volume and Growth Rate Forecast by Region (2017-2022)
        15.2.2 Asia-Pacific Non-Insulin Therapies for Diabetes Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.3 China Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.4 Japan Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.5 South Kore